Staging β-amyloid pathology with amyloid positron emission tomography

What The Study Did: This multicenter study used in vivo β-amyloid cerebrospinal fluid, a biomarker of Alzheimer disease, and positron emission tomography findings to track progression of Alzheimer disease over six years among study participants.

Authors: Niklas Mattsson, M.D., Ph.D., and Oskar Hansson, M.D., Ph.D., of Lund University in Malmo, Sweden, are the corresponding authors.

(doi:10.1001/jamaneurol.2019.2214)

Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Credit: 
JAMA Neurology